Bharat Biotech provides COVID-19 vaccine Covaxin to the central authorities at Rs 150 per dose
Hyderabad:
The provide worth of Bharat Biotech’s COVID-19 vaccine Covaxin to the central authorities at Rs 150 per dose just isn’t sustainable in the long term, the vaccine maker mentioned on Tuesday.
The Centre’s supplying worth is pushing the pricing construction for the non-public sector upward.
“Fundamental business reasons ranging from low procurement volumes, high distribution costs and retail margins among few others contribute to higher pricing of Covaxin,” Bharat Biotech mentioned justifying the upper worth when in comparison with different COVID-19 vaccines accessible for the non-public sector in India.
“The supply price of Covaxin to the government of India at Rs 150 / dose, is a non-competitive price and clearly not sustainable in the long run. Hence a higher price in private markets is required to offset part of the costs,” Bharat Biotech mentioned in a press release.
Bharat Biotech has to this point invested over Rs 500 crores in danger from its personal sources for product improvement, medical trials and organising of producing services for Covaxin, it added.
(Except for the headline, this story has not been edited by NDTV workers and is printed from a syndicated feed.)
